FDA 483 - Baxalta US Incorporated

An FDA inspection of Baxalta US Inc. in Los Angeles, CA, a blood fractionation manufacturing facility, identified two observations related to quality control. The firm failed to repeat environmental monitoring performance qualification studies and a washer study, despite these studies not meeting their predefined acceptance criteria. This indicates a deficiency in ensuring the validity and reliability of critical manufacturing processes.